GEOapplication/xmlftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE319nnn/GSE319777/primaryOK200Methylation profilingHomo sapiensMethylation profiling by arrayhttps://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE319777GEOGSEfalseTherapeutic TG2 Inhibition Reverses Systemic Multiomic Dysregulation in Celiac DiseaseBackground and Aims: Celiac disease (CeD) is an autoimmune disease triggered by dietary gluten in genetically predisposed individuals. Deamidation of gluten peptides by the CeD autoantigen and enzyme transglutaminase 2 (TG2) is central to the pathogenesis of CeD. Inhibition of TG2 with the specific inhibitor ZED1227 effectively prevents gluten-induced histological damage in CeD patients. Here we aimed to explore the blood DNA methylomic changes in ZED1227-treated CeD patients undergoing a gluten challenge. Results: Drug treatment revealed consistent patterns suggesting normalization of the DNA methylome indicating that ZED1227 attenuated the systemic responses to gluten challenge. Conclusions: These findings provide evidence that ZED1227 can significantly prevent the gluten-induced CeD-associated systemic changes. Clinical trial: EudraCT 2017-002241-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 sapiens[42032651]